AAAAAA

   
Results: 1-14 |
Results: 14
Gene transfer using human papillomavirus pseudovirions varies according tovirus genotype and requires cell surface heparan sulfate
Authors: Combita, AL Touze, A Bousarghin, L Sizaret, PY Munoz, N Coursaget, P
Citation: Al. Combita et al., Gene transfer using human papillomavirus pseudovirions varies according tovirus genotype and requires cell surface heparan sulfate, FEMS MICROB, 204(1), 2001, pp. 183-188
Prevalence of anti-human papillomavirus type 16, 18, 31, and 58 virus-likeparticles in women in the general population and in prostitutes
Authors: Touze, A de Sanjose, S Coursaget, P Almirall, MR Palacio, V Meijer, CJL Kornegay, J Bosch, FX
Citation: A. Touze et al., Prevalence of anti-human papillomavirus type 16, 18, 31, and 58 virus-likeparticles in women in the general population and in prostitutes, J CLIN MICR, 39(12), 2001, pp. 4344-4348
Gene transfer using human polyomavirus BK virus-like particles expressed in insect cells
Authors: Touze, A Bousarghin, L Ster, C Combita, AL Roingeard, P Coursaget, P
Citation: A. Touze et al., Gene transfer using human polyomavirus BK virus-like particles expressed in insect cells, J GEN VIROL, 82, 2001, pp. 3005-3009
The nine C-terminal amino acids of the major capsid protein of the human papillomavirus type 16 are essential for DNA binding and gene transfer capacity
Authors: Touze, A Mahe, D El Mehdaoui, S Dupuy, C Combita-Rojas, AL Bousarghin, L Sizaret, PY Coursaget, P
Citation: A. Touze et al., The nine C-terminal amino acids of the major capsid protein of the human papillomavirus type 16 are essential for DNA binding and gene transfer capacity, FEMS MICROB, 189(1), 2000, pp. 121-127
Gene transfer using recombinant rabbit hemorrhagic disease virus capsids with genetically modified DNA encapsidation capacity by addition of packaging sequences from the L1 or L2 protein of human papillomavirus type 16
Authors: El Mehdaoui, S Touze, A Laurent, S Sizaret, PY Rasschaert, D Coursaget, P
Citation: S. El Mehdaoui et al., Gene transfer using recombinant rabbit hemorrhagic disease virus capsids with genetically modified DNA encapsidation capacity by addition of packaging sequences from the L1 or L2 protein of human papillomavirus type 16, J VIROLOGY, 74(22), 2000, pp. 10332-10340
Marek's disease virus (MDV) homologues of herpes simplex virus type 1 UL49(VP22) and UL48 (VP16) genes: high-level expression and characterization of MDV-1 VP22 and VP16
Authors: Dorange, F El Mehdaoui, S Pichon, C Coursaget, P Vautherot, JF
Citation: F. Dorange et al., Marek's disease virus (MDV) homologues of herpes simplex virus type 1 UL49(VP22) and UL48 (VP16) genes: high-level expression and characterization of MDV-1 VP22 and VP16, J GEN VIROL, 81, 2000, pp. 2219-2230
Identification of a novel hepatitis E virus in Nigeria
Authors: Buisson, Y Grandadam, M Nicand, E Cheval, P van Cuyck-Gandre, H Innis, B Rehel, P Coursaget, P Teyssou, R Tsarev, S
Citation: Y. Buisson et al., Identification of a novel hepatitis E virus in Nigeria, J GEN VIROL, 81, 2000, pp. 903-909
DNA-containing and empty hepatitis B virus core particles bind similarly to envelope protein domains
Authors: Hourioux, C Touze, A Coursaget, P Roingeard, P
Citation: C. Hourioux et al., DNA-containing and empty hepatitis B virus core particles bind similarly to envelope protein domains, J GEN VIROL, 81, 2000, pp. 1099-1101
Human papillomavirus vaccines
Authors: Breitburd, F Coursaget, P
Citation: F. Breitburd et P. Coursaget, Human papillomavirus vaccines, SEM CANC B, 9(6), 1999, pp. 431-445
Comparison of the humoral and cellular immune responses to two preparations of Cryptosporidium parvum CP15/60 recombinant protein
Authors: Iochmann, S Sagodira, S Melevec, MN Reperant, JM Naciri, M Coursaget, P Bout, D
Citation: S. Iochmann et al., Comparison of the humoral and cellular immune responses to two preparations of Cryptosporidium parvum CP15/60 recombinant protein, MICROB PATH, 26(6), 1999, pp. 307-315
Vaccination against infectious agents associated with human cancer
Authors: Coursaget, P Munoz, N
Citation: P. Coursaget et N. Munoz, Vaccination against infectious agents associated with human cancer, CANC SURV, 33, 1999, pp. 355-381
Baculovirus expression of chimeric hepatitis B virus core particles with hepatitis E virus epitopes and their use in a hepatitis E immunoassay
Authors: Touze, A Enogat, N Buisson, Y Coursaget, P
Citation: A. Touze et al., Baculovirus expression of chimeric hepatitis B virus core particles with hepatitis E virus epitopes and their use in a hepatitis E immunoassay, J CLIN MICR, 37(2), 1999, pp. 438-441
Nasal immunization of mice with human papillomavirus type 16 (HPV-16) virus-like particles or with the HPV-16 L1 gene elicits specific cytotoxic T lymphocytes in vaginal draining lymph nodes
Authors: Dupuy, C Buzoni-Gatel, D Touze, A Bout, D Coursaget, P
Citation: C. Dupuy et al., Nasal immunization of mice with human papillomavirus type 16 (HPV-16) virus-like particles or with the HPV-16 L1 gene elicits specific cytotoxic T lymphocytes in vaginal draining lymph nodes, J VIROLOGY, 73(11), 1999, pp. 9063-9071
Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia I. Differential T-helper and IgG responses in relation to HPV infection and disease outcome
Authors: de Gruijl, TD Bontkes, HJ Walboomers, JMM Coursaget, P Stukart, MJ Dupuy, C Kueter, E Verheijen, RHM Helmerhorst, TJM Duggan-Keen, MF Stern, PL Meijer, CJLM Scheper, RJ
Citation: Td. De Gruijl et al., Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia I. Differential T-helper and IgG responses in relation to HPV infection and disease outcome, J GEN VIROL, 80, 1999, pp. 399-408
Risultati: 1-14 |